Your browser doesn't support javascript.
loading
Doses of hepatitis B revaccination needed for the seronegative youths to be seropositive to antibody against hepatitis B surface antigen.
Jan, Chyi-Feng; Liu, Tzu-Hung; Ho, Chien-Han; Chien, Yin-Chu; Chang, Che-Jui; Guo, Fei-Ran; Huang, Kuo-Chin.
Afiliação
  • Jan CF; Department of Family Medicine, National Taiwan University Hospital, Taipei, Taiwan.
  • Liu TH; Department of Family Medicine, College of Medicine, National Taiwan University, Taipei, Taiwan.
  • Ho CH; Department of Family Medicine, National Taiwan University Hospital, Taipei, Taiwan.
  • Chien YC; Department of Family Medicine, National Taiwan University Hospital, Taipei, Taiwan.
  • Chang CJ; Genomics Research Center, Academia Sinica, Taipei, Taiwan.
  • Guo FR; Department of Family Medicine, National Taiwan University Hospital, Taipei, Taiwan.
  • Huang KC; Department of Family Medicine, National Taiwan University Hospital, Taipei, Taiwan.
Fam Pract ; 37(1): 30-35, 2020 02 19.
Article em En | MEDLINE | ID: mdl-31375819
ABSTRACT

OBJECTIVES:

To determine the required hepatitis B vaccine doses for subjects who were seronegative for three hepatitis B seromarkers during their youth who wish to have seroprotective antibodies against the hepatitis B surface antigen (anti-HBs).

METHODS:

We conducted a retrospective cohort study. From 2012 to 2015, graduate school students born after 1986 who were seronegative for three hepatitis B virus seromarkers at college entrance (n = 1037) were recruited. Four groups of subjects received zero to three doses of a hepatitis B vaccine booster at their free willingness, and their anti-HBs titre were measured at their graduate school entrance. Very low and extremely low antibody titres against the hepatitis B surface antigen were elucidated by graphic inference to determine the required booster dose cut-off value for seropositivity after revaccination.

RESULTS:

The anti-HBs seropositive rates in the four groups of subjects receiving the hepatitis B booster vaccine(s) were 17.7%, 52.1%, 78.6% and 90.9% for those receiving zero, one, two and three doses, respectively. In subjects with very low antibody titres against the hepatitis B surface antigen after one dose of the vaccine booster and subjects with an extremely low titre after two doses of the booster, the seropositive rates reached 95% at the cut-off value of 3 mIU/ml.

CONCLUSION:

A seropositive rate of at least 95% can be reached by the administration of two hepatitis B booster doses to youths with extremely low antibody titres against the hepatitis B surface antigen (<3 mIU/ml) and administering one dose to those with very low titres (3-10 mIU/ml) at college.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Imunização Secundária / Vacinas contra Hepatite B / Hepatite B / Anticorpos Anti-Hepatite B / Antígenos de Superfície da Hepatite B Tipo de estudo: Etiology_studies / Incidence_studies / Observational_studies / Risk_factors_studies Limite: Adolescent / Adult / Female / Humans / Male País/Região como assunto: Asia Idioma: En Ano de publicação: 2020 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Imunização Secundária / Vacinas contra Hepatite B / Hepatite B / Anticorpos Anti-Hepatite B / Antígenos de Superfície da Hepatite B Tipo de estudo: Etiology_studies / Incidence_studies / Observational_studies / Risk_factors_studies Limite: Adolescent / Adult / Female / Humans / Male País/Região como assunto: Asia Idioma: En Ano de publicação: 2020 Tipo de documento: Article